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IntroductIon Viral hepatitis caused by the hep‑
atitis C virus (HCV) is now one of the most se‑
rious health problems. This results from spread‑
ing of this virus worldwide, various routes of its 
transmission and lack of truly efficient therapy. 
In about 80% of patients acute hepatitis C pro‑
gresses into a chronic disease, chronic hepatitis 
C after years of infection leads to a series of com‑
plications that mark this disease, and then quite 
commonly to death.1
The HCV was discovered in the USA in 1989.2 
It is a flavivirus containing a single RNA strand 
made up of approximately 10,000 nucleotides 
and encapsuled by an external lipid envelope. 
The diameter of the virus is about 50–60 nm.1 
The HCV is a highly heterogenous virus. There 
are at least 6 genotypes of the virus, marked 
from 1 to 6, and more than 50 subtypes marked 
with letters (e.g. 1a, 1b, 2a, 2b). Nucleotide se‑
quences of the individual virus genotypes differ 
by approximately 31–34%, and by about 20–23% 
in the group of subtypes.3 Because of the large 
genome variability and frequent mutations, 
a population of HCV in an infected patient is het‑
erogenous, and helps the virus to survive the host 
immune system defense mechanisms. As a re‑
sult, the HCV with altered features is not elim‑
inated from the body by anti‑HCV antibodies, 
which can only prove the infection (like an HIV 
infection).1
Epidemio­logical­data According to World Health 
Organization data, 3% of the human population, 
i.e. approximately 170 million people, is infect‑
ed with HCV. The prevalence of HCV chronic in‑
fection is 0.1% to 26% and varies in different re‑
gions.1,4 The prevalence of HCV infection in East‑
ern Europe is about 0.7–4.9%.2 In Poland, the per‑
centage of people in whom anti‑HCV antibodies 
have been detected is about 1.4%, which amounts 
to approximately 500,000 people. According 
to the most recent data, this number is under‑
estimated, and the presumed number of the in‑
fected persons is over 750,000. According to data 
from the National Department of Hygiene and 
from the Chief Sanitary Inspectorate, in recent 
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AbstrAct
Hepatitis C is caused by the hepatitis C virus (HCV) infection. According to World Health Organi-
zation data, 3% of the world population (approximately 170 million people) is infected with HCV; 
in Poland there are over 700,000. Over 70% of those infected manifest no symptoms in the acute 
phase of the disease, and in about 70–80% the acute phase progresses into a chronic form. Patients 
with symptoms in the acute phase of HCV infection most commonly present with unspecific signs 
and symptoms that may develop in other viral liver infections, e.g. malaise, fatigue, abdominal pain, 
mild hepato- and splenomegaly and arthralgia. These symptoms usually persist for 2 to 12 weeks. 
In the chronic phase a subset of patients complain of malaise, nausea, abdominal pain and itching. 
With time, chronic hepatitis C may develop into liver cirrhosis. The basic diagnostic methods in HCV 
infection involve determination of anti-HCV antibodies using the ELISA immunoassay and examination 
of HCV-RNA with the RT-PCR method. The current treatment of HCV infection involves administration 
of pegylated inter feron α and ribavirin over a period of 48 weeks in HCV-1 genotype infection, and 
24 weeks for HCV-2 and 3 genotypes. Effectiveness of therapy depends on the HCV genotype. HCV 
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a mother to a child and the timing of the contrac‑
tion are still unclear. It is not known whether 
contracting the disease could occur during preg‑
nancy, at birth, after delivery or while breast‑
feeding. There is no evidence as yet for transmis‑
sion through mother’s milk. At present, the ways 
to protect a child against HCV infection are un‑
known. More commonly, the infection of a child 
takes place in acute hepatitis C in the third trimes‑
ter of pregnancy, and when accompanied by HIV 
infection. It should be highlighted that just after 
birth the anti‑HCV antibodies can be detected 
in child’s blood (persisting even up to 1.5 years), 
passively transmitted from the mother; this phe‑
nomenon is of no significance in pathogenesis 
of HCV infection.8
Sexual transmission as a route of HCV infec‑
tion is estimated to occur in 2 to 27% of patients, 
depending on the study; on average no more than 
15% of such cases are approved as most probable. 
The rate of infected individuals correlates with 
the number of sexual encounters, with prosti‑
tutes and intravenous drug users being the most 
commonly affected. Variable epidemio logical data 
are reported for homo sexuals.3 Similarly, incon‑
sistent data about the intrafamilial transmis‑
sion have been published. It is estimated that 
the prevalence of HCV infection is 6–23% among 
spouses.
History­and­clinical­presentation­of­hepatitis­c 
The incubation period of HCV is usually 15–150 
days from the moment of exposure, with an aver‑
age of 40–50 days. The antibodies can be detected 
4 weeks from the time of contraction at the ear‑
liest, but most commonly this period exceeds 10 
weeks. No antibodies are detected in about 7% 
of patients. In more than 70% of cases, patients 
exhibit no signs and symptoms. Non‑character‑
istic signs or symptoms are reported in 10–30% 
of cases, and they involve mild stomach discom‑
fort, sometimes flu‑like symptoms, myalgia, ar‑
thralgia and low‑degree fever. Jaundice and liver 
enlargement are rare and occur in approximate‑
ly ⅓ of patients. Serum alanine aminotransferase 
(ALT) activity is usually elevated and may be 10 
times normal. A fulminatant hepatitis C is very 
infrequently reported in an acute phase. How‑
ever, in 70–80% of patients there is a progres‑
sion into a chronic process. The infection with 
HCV along with the confirmed lack of HCV‑RNA 
in the liver tissue after infection does not neces‑
sarily mean that such an individual will not be 
re‑infected.1,3
In the course of long‑standing chronic hepati‑
tis, gradual damage to the liver develops. Basical‑
ly, most individuals with chronic hepatitis do not 
exhibit any symptoms for a long time. The only 
sign of the disease may be fatigue. Dyspepsia 
or itching appear rarely. Serum ALT levels are 
normal or slightly elevated. Infrequently, serum 
γ‑glutamyl transpeptidase, alkaline phosphatase 
and bilirubin levels are slightly increased. After 
20 years liver cirrhosis develops and its typical 
times approximately 2000 people every year are 
infected with HCV in Poland.3,5
There are 6 types and numerous subtypes 
of HCV. Genotype 1 is the most common – it is 
present 40–80% of all patients with HCV chron‑
ic infection. Genotype 1 prevails in the USA, but 
in Europe and Japan genotypes 2 and 3 are more 
common. Genotype 4 is the most common geno‑
type in Egypt and the Middle East. In southern Af‑
rica genotype 5 is most prevalent, for Hong Kong 
and other countries of south‑eastern Asia it is 
genotype 6; genotypes 4, 5 and 6 are rarely found 
outside of those African or Asian regions. In Po‑
land, about 80% of patients are infected with gen‑
otype 1b virus.6,7
routes­of­transmission­of­hepatitis­c Hepatitis C 
may spread through blood and blood products, 
sexual contact, and vertically. There are also “oc‑
casional” infections, which account for as many 
as 40% of all chronic hepatitis C cases. They can 
be diagnosed as such when the source of infec‑
tion is unknown.
Blood infection may result from a blood trans‑
fusion or an organ transplant, it may occur dur‑
ing invasive diagnostic procedures (e.g. organ 
bio psies, endoscopic examination). There are 
approximately 105 to 107 viral particles in 1 ml 
of blood of an infected patient with the chron‑
ic form of the disease, and up to 109/ml in about 
15% of patients. The quantity of the virus in body 
fluids and tissues is much lower.3 A high incidence 
of infection in Poland is reported in the drug ad‑
dict population who use intravenous narcotics; 
this is approximately 57–90% of cases. Drug us‑
ers infected with HIV more frequently contract 
HCV. There are 2 groups of patients particularly 
prone to the infection: hemo philiacs and patients 
receiving hemo dialysis. It is estimated that ap‑
proximately 50–90% of hemo philiacs worldwide 
are infected with HCV.3 This is caused by numer‑
ous blood transfusions and blood product infu‑
sions, however, the introduction of new diagnos‑
tic methods in blood therapy has significantly low‑
ered the risk of transmission.
The incidence of anti‑HCV antibodies in 
the blood of patients receiving hemo dialysis 
depends on the duration of dialysis and grows 
with the frequency of the procedure. It is estimat‑
ed that the incidence of HCV infections in this 
group is about 10–20% worldwide, and in Poland 
it reaches 30–58%.3
When a donor of n organ transplant is an HCV‑
‑infected person, a transmission of the virus occurs 
in 50% of patients. When immunotherapy is in‑
cluded into the treatment of a patient infected with 
HCV following transplantation, a chronic or fulmi‑
nant form of hepatitis C frequently occurs.1
The infection can also be acquired through 
an occupational exposure to blood, basically 
in health care workers, but also policemen, city 
guards, and penitentiary workers.
The HCV infection can also be the result of per‑
inatal exposure. The routes of transmission from 
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The sensitivity and specificity of these tests are ap‑
proximately 99%. The presence of anti‑HCV anti‑
bodies in serum alone is no evidence of HCV infec‑
tion. The antibodies may be detected in those in‑
dividuals who have a history of hepatitis C. More‑
over, HCV infection may occur in immunosup‑
pressive patients with no detectable anti‑HCV 
antibodies. Another type of investigation that 
can confirm HCV which should be performed 
following the detection of anti‑HCV antibodies 
in serum is the estimation of HCV genetic ma‑
terial in the blood. The RT‑PCR assay (reverse 
transcription polymerase chain reaction) with 
a sensitivity of 98% is most commonly used. For 
a quantitative evaluation of the virus, which is 
essential for assessment of the anti‑viral treat‑
ment effectiveness, branched DNA and PCR as‑
says are used. These tests t are able to evaluate 
the core HCV antigen (HCVAg), and are useful 
in diagnostic evaluation within the “sero logical 
window”, i.e. before anti‑HCV antibodies are pres‑
ent.13-15 The earliest sero logical marker of the HCV 
infection is HCV‑RNA, which can usually be de‑
tected 1–2 weeks after the onset of the infection. 
Then, with a delay of 1–1.5 days, HCVAg appears. 
Anti‑HCV antibodies may be detected, on aver‑
age, 3–8 weeks after contracting the infection, 
most commonly 34 days after the moment when 
HCV‑RNA appears in the blood.3
Histo­logical­lesions­in­the­liver Inflammatory 
infiltration, fibrosis and degeneration of hepa‑
tocytes represent histo logical lesions in the liv‑
er during the course of hepatitis C, both in its 
acute and chronic phase. Inflammatory infiltra‑
tions are located intralobularly and in the portal 
area, and consist of lymphocytes, plasmocytes 
and antigen‑presenting cells. The degenerating 
cells are swollen, demonstrate acidophilic degen‑
erative lesions, acidophilic particles or Council‑
man‑like bodies. Approximately 50% of patients 
with hepatitis C display features of liver steato‑
sis. Hepatocyte necrosis may be focal or conflu‑
ent. When a confluent necrosis leads to a fusion 
of vascular structures of portal areas, it is de‑
scribed as a bridging necrosis. The topography 
of inflammatory and degenerative lesions of he‑
patocytes depends on the phase of inflammation; 
in an acute phase lobular lesions prevail, where‑
as in a chronic phase lesions in the portal areas 
are usually more common.
A histopatho logical presentation of the HCV 
infection is similar to the lesions occuring 
in the HBV infection. However, the damage 
to the bile duct system, formation of the lymph 
follicles in portal areas, focal macrovesicular ste‑
atosis (coarse droplets) and, occasionally, pres‑
ence of Mallory’s bodies are more frequently re‑
ported in hepatitic C.16 (tAbLE­1, tAbLE­2)
treatment­with­inter­feron­α­and­ribavirin Treat‑
ment of chronic hepatitis C viral infection is one 
of the most serious issues in contemporary med‑
icine. The rate of patients with a spontaneous 
symptoms and complications occur in about 20% 
of patients.8-12
Mortality among patients with liver cirrhosis 
induced by HCV infection – resulting from the de‑
velopment of portal hypertension, liver failure or 
primary liver cancer (HCC) – reaches 2–5% year‑
ly, whereas the prevalence of HCC development 
is about 1–4% per year.1,3
diagnostics­of­HcV­infection Once HCV was dis‑
covered (in 1989), and generations of tests ap‑
peared, the rate of infection through blood trans‑
fusions and organ transplants decreased. Before 
1989, blood was considered a potentially conta‑
gious material (and a blood donor as a potentially 
infected person) when serum ALT levels were high. 
The 1st generation ELISA test introduced in May 
1990 had a sensitivity of 46%, the 2nd genera‑
tion ELISA test (July, 1991) was sensitive to 60%, 
the RIBA‑II test (recombinant immunoblot assay 
II) increased its sensitivity to 90%. Studies per‑
formed in 1992 in the USA showed the risk of con‑
tracting HCV infection during a blood transfusion 
to be as high as 4%, whereas after introduction 
of the 2nd generation tests (ELISA, RIBA‑II), it 
declined to 0.6%. The 3rd generation ELISA test 
is highly sensitive and its sensitivity exceeds 99%, 
and an additional assay of HCV‑RNA by PCR tech‑
nique further limits the chance of transfusion‑me‑
diated HCV infection.3
Recent diagnostic procedures for the detec‑
tion of HCV involve application of 3rd genera‑
tion ELISA tests, containing core antigens (C) 
and at least 2 antigens of non‑structural proteins. 
tAbLE­1 The progress of necrotic inflammatory process activity (G) in portal and 
periportal areas and in the lobules, scored from 0 to 4 according to Batts-Ludwig17
0 inflammatory lesions limited to the portal area, no piecemeal necrosis or 
characteristics of lobular inflammation (a presentation which corresponds to 
hepatitis chronica persistens in classic terminology)
1 periportal inflammatory infiltration, focal piecemeal necrosis and lobular 
inflammatory lesions of a minor degree (hepatitis chronica activa minimalis)
2 periportal inflammatory, focal piecemeal necrosis around some portal areas 
and intralobular inflammatory lesions of a minor degree (hepatitis chronica activa 
minoris gradus)
3 periportal inflammatory infiltration, piecemeal necrosis around all portal areas 
and lobular inflammatory lesions of a moderate degree (hepatitis chronica activa 
mediocris gradus)
4 periportal inflammatory infiltration, piecemeal necrosis of a high degree, 
coexistence of inflammatory lesions of a bridging type (portal-venous), widespread 
damage to hepatic cells (hepatitis chronica activa maioris gradus)
tAbLE­2 The progression of fibrosis (S) in the liver, scored from 0 to 4 according 
to Batts-Ludwig17
0 none
1 fibrosis in portal areas
2 periportal fibrosis, presence of single septa (barriers) between neighboring 
portal areas
3 presence of fibrous septa connecting neighboring portal areas, and portal areas 
with a central lobular vein, initial distortion of the lobule architecture
4 cirrhosis – modeling of the liver and regenerative nodules present
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and fibrosis. Schiffman et al. have claimed that pa‑
tients with normal ALT activity should be treated 
using the same approach as those with increased 
ALT activity,24 which has been widely approved 
in the current therapeutic recommendations.
Important data have been presented by Prati 
et al. who have shown that patients with normal 
ALT activity, treated with PEG‑IFN and ribavirin, 
achieve SVR (sustained viro logical response) and 
exhibit a further decrease in ALT activity. The au‑
thors suggest that the upper limit of the reference 
range for ALT should be revised.25
At present, the American Association for 
the Study of Liver Diseases recommends the fol‑
lowing approach in the evaluation of patients 
with chronic hepatitis C who qualify for antivi‑
ral therapy. The patients are assigned to 3 groups. 
The first 2 groups involve patients with clear indi‑
cations or contraindications. The 3rd group con‑
sists of the patients with no definite signs re‑
quired to introduce treatment, and who should 
be evaluated on an individual basis. Patients with 
the confirmed presence of virus genetic materi‑
al (positive HCV‑RNA) are selected for the treat‑
ment. Recommendations are presented in tAbLEs­4, 
5 and 6.26
The purpose of the HCV infection treatment 
is the permanent inhibition of virus replication, 
arresting or slowing the progress of histo logical 
lesions in the liver, and the bio chemical normal‑
ization of liver function para meters. Nucleotide 
sequence variability observed in particular gen‑
otypes and subtypes of virus has a serious im‑
pact on the response to treatment. Genotype 
1 and 4 are less susceptible to treatment. This 
variability makes the development of a vaccine 
difficult.27,28
In the recent years, promising attempts have 
been made to treat acute hepatitis C. It turned 
out that the effectiveness of therapy with inter‑
feron α in this group of patients is higher than 
in those with inter feron and ribavirin in pa‑
tients with chronic hepatitis C. Sustained virall 
response in patients with acute hepatitis C treat‑
ed with inter feron α amounts to approximate‑
ly to 70–95%. At the same time, there are insuf‑
ficient data to assess which patients should be 
treated, in what period of time the antiviral ther‑
apy should be introduced and how long the ther‑
apy should be conducted. Given the preliminary 
data, it appears that the therapy should be de‑
layed by about 12 weeks from the onset of symp‑
toms. At that time approximately 15–20% of pa‑
tients spontaneously eliminate the virus. Avail‑
able meta‑analyses show that the 2–3‑month de‑
lay in therapy has no negative impact on SVR. It 
also seems that the inclusion of ribavirin into 
the regimen does not improve SVR.29-31
After antiviral treatment, patients should still 
be taken care of by the Viral Hepatitis Out‑Patient 
Clinic. In those patients who have not presented 
SVR, the liver function tests, α‑fetoproteins and 
the USG of the abdomen should be performed ev‑
ery 6–12 months. Furthermore, another course 
clearance of the virus in this disease is the low‑
est out of all forms of viral hepatitis. The course 
of chronic hepatitis C is usually rather slow, but 
it inevitably leads to severe complications, in‑
cluding liver cirrhosis and HCC. If the condition 
affects young individuals with a potentially long 
life expectency, development of such complica‑
tions is almost certain.
Currently, a combination of pegylated inter‑
feron α (PEG‑IFN) and ribavirin over a period 
of 24–48 weeks is used in the treatment of chron‑
ic hepatitis C. Previously, a recombinant form 
of inter ferons was used, replaced finally by a re‑
combinant PEG‑IFN.
Introduction of pegylated inter ferons has im‑
proved the effectiveness of the therapy for HCV 
infection. PEG‑IFN α is the inter feron conjugat‑
ed with polyethylene glycol with a long half‑life 
and improved bio availability. Due to the introduc‑
tion of the polyethylene glycol molecule, the drug 
remains longer in the bloodstream and its blood 
level is more stable.3,18
The effectiveness of treatment with inter feron 
α and ribavirin reaches 37–42%, whereas that 
of PEG‑IFN and ribavirin in patients with a non‑1 
genotype amounts to 78%, and to 55% in patients 
with a 1 genotype.3,19-23
The adverse reactions of inter feron and riba‑
virin are shown in tAbLE­3.1,3,4
Inclusion criteria for patients with chronic hep‑
atitis C to receive antiviral treatment has changed 
over the last few years. Initially, patients with 
chronic hepatitis C with the persistent elevated 
ALT activity for more than 6 months, compensat‑
ed liver function, histo logical lesions in the liver 
(fibrosis, inflammation) and without contraindi‑
cations were eligible to treatment. Such treatment 
lasted from 24 to 48 weeks, depending on the vi‑
rus genotype, and was 40% effective. In recent 
years, the concept that the progress of the disease 
is very slow in patients with normal ALT activity 
has been challenged. Shiffman et al. have report‑
ed data regarding 480 patients with chronic hepa‑
titis C exhibiting normal ALT activity and a lesser 
progression of lesions on histo logical examination 
than patients with high ALT activity combined 
with advanced necrotic and inflammatory lesions 
tAbLE­3 Adverse effects of interferon and ribavirin
Adverse effects of interferon
fever
flu-like symptoms




Adverse effects of ribavirin
hemolysis
increased plasma uric acid levels
cough
rash, itching
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is observed after accidental injury with a needle 
or other sharp device stained with HCV infect‑
ed blood – this amounts to approximately 1.8%. 
The risk of the infection from the mucosa’s con‑
tact with a HCV‑positive patient’s blood is very 
low, and, as yet, there are no reports on the trans‑
mission of HCV infection by spills on the skin. 
The basic technique used for prevention of HCV 
infections (and also HBV, HIV) in profession‑
al practice is proper staff training. Employers 
should provide health care workers with ongoing 
access to a doctor. Each staff member should im‑
mediately report exposure to contagious material 
to a designated doctor, who will evaluate the risk 
of having contracted HCV infection and under‑
take the adequate procedure. Wounds and skin 
contaminated with a contagious material should 
be washed with soap and water, while the muco‑
sa can be just rinsed with water. There is no ev‑
idence confirming antiseptic agents to be more 
effective, though they are not contraindicated. 
There is no reliable data pointing to the effec‑
tiveness of immunoglobulins in post‑exposure 
practice. Available data show that inter feron is 
only effective for full‑blown hepatitis C. Base‑
line serum anti‑HCV antibodies and ALT activ‑
ity in an exposed person should be determined, 
and, in the event of the absence of HCV antibod‑
ies, the tests should be repeated after 6 weeks, 
and then after 3 and 6 months.32,33
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